Sunday, June 11, 2006

Diabetes Mellitus - Novartis, Merck Face Off Over New Diabetes Drugs

Novartis, Merck Face Off Over New Diabetes Drugs
Bio-IT World - Jun 09 7:45 AM
June 09, 2006 | Novartis's Galvus and Merck's Januvia stand to enter the lucrative -- but highly competitive -- market of oral treatments for Type 2 diabetes. Both have been touted by analysts as potential $1 billion-a-year plus sellers.Save to My Web

Positive data for Depomed diabetes drug
Pharmaceutical Business Review - Jun 09 7:32 AM
A phase III trial of Depomeds Glumetza, a once-daily metformin tablet for the treatment of type 2 diabetes mellitus, has shown that adding the drug to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone.Save to My Web

Phenomix diabetes drug enters phase II
Pharmaceutical Business Review - Jun 09 6:16 PM
Phenomix Corporation has initiated a phase II clinical trial of PHX1149, a novel orally administered inhibitor of DPP4 for the treatment of type 2 diabetes.Save to My Web

Nektar Reports Pfizer Announcement of New Exubera Data
[Press Release] Business Wire via Yahoo! Finance - Jun 10 9:30 AM
WASHINGTON----June 10, 2006--Nektar Therapeutics : Principal Investigator: "Exubera is a valuable new option that could improve earlier acceptance of insulin among people with type 2 diabetes, and potentially reduce the debilitating and costly complications associated with the disease."Save to My Web

Many Doctors Aren't Treating Diabetes Aggressively Enough
Health Scout - Jun 10 10:05 AM
This is true for patients with high blood pressure, elevated blood sugar, studies find.Save to My Web

Diabetes Mellitus